Switching ET and Adding Ribociclib Improves PFS in HR+, HER2- Breast Cancer
Patients with HR+, HER2- metastatic breast cancer whose disease progressed on endocrine therapy (ET) and a CDK4/6 inhibitor have better progression-free survival if they switch ET and receive ribociclib than if they switch ET alone, a phase 2 study suggests.